Human Reproduction, Vol 13, 3371-3378, Copyright © 1998 by Oxford University Press
I Sivin, I Campodonico, O Kiriwat, P Holma, S Diaz, L Wan, A Biswas, O Viegas, K el din Abdalla, MP Anant, M Pavez and J Stern
A new contraceptive (LNG rod implants, Jadelle, Leiras Oy's registered
trademark for rod implants) was prospectively evaluated in randomized 5
year comparison with Norplant (Population Council's registered trademark
for contraceptive implants releasing levonorgestrel) capsule implants. The
study involved 1198 women at seven centres. No pregnancies occurred in the
first 4 years. At 5 years, the cumulative pregnancy rate was 1 per 100
users or less for each regimen. Annual discontinuation rates averaged 11-12
per 100 users (P > 0.05), corresponding to 5 year continuation rates of
55.1 for rods and 53.0 per 100 for capsules. Mean annual discontinuation
rates for menstrual disturbances were 3.5 and 4.2 per 100 for rod and
capsule implants respectively (P > 0.05), and mean annual removal rates
for medical problems were 3.5 and 3.0 per 100 (P > 0.05) respectively.
Apart from menstrual problems, headache, weight gain and acne were the
principal medical reasons for removal. In proportional hazard analyses,
family formation variables, age, parity and desire/non desire for another
child, recorded at admission, significantly affected discontinuation rates
for major decrement categories and for all reasons combined. Mean rod
removal time was half that of Norplant (P < 0.01); complications of rod
removal were at a lower rate. With these contraceptives indistinguishable
in performance except for ease and speed of removal, LNG rod implants
appear to be preferable to Norplant for use through 5 years by virtue of
relative ease of removal.
ARTICLES
The performance of levonorgestrel rod and Norplant contraceptive implants: a 5 year randomized study
Center for Biomedical Research, The Population Council, New York 10021, USA.
![]()
CiteULike
Connotea
Del.icio.us What's this?